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Abstract Stimulant prescription rates for attention deficit hy-
peractivity disorder (ADHD) are increasing, even though po-
tential long-term effects on the developing brain have not been
well-studied. A previous randomized clinical trial showed
short-term age-dependent effects of stimulants on the DA sys-
tem.We here assessed the long-term modifying effects of age-
of-first-stimulant treatment on the human brain and behavior.
81 male adult ADHD patients were stratified into three
groups: 1) early stimulant treatment (EST; <16 years of age)
2) late stimulant treatment (LST: ≥23 years of age) and 3)
stimulant treatment naive (STN; no history of stimulant treat-
ment). We used pharmacological magnetic resonance imaging
(phMRI) to assess the cerebral blood flow (CBF) response to
an oral methylphenidate challenge (MPH, 0.5 mg/kg), as an
indirect measure of dopamine function in fronto-striatal areas.
In addition, mood and anxiety scores, and recreational drug
use were assessed. Baseline ACC CBF was lower in the EST
than the STN group (p = 0.03), although CBF response to
MPH was similar between the three groups (p = 0.23).
ADHD symptom severity was higher in the STN group com-
pared to the other groups (p < 0.01). In addition, the EST
group reported more depressive symptoms (p = 0.04), but
not anxiety (p = 0.26), and less recreational drug use
(p = 0.04). In line with extensive pre-clinical data, our data
suggest that early, but not late, stimulant treatment long-
lastingly affects the human brain and behavior, possibly indi-
cating fundamental changes in the dopamine system.
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Introduction
Attention-deficit hyperactivity disorder (ADHD) is one of the
most common psychiatric disorders diagnosed in children and
adolescents (Thomas et al. 2015), and also has a high preva-
lence in adults (approximately 2.5%) (Simon et al. 2009). The
most prescribed treatment for ADHD is stimulant medication,
such as methylphenidate (MPH) and dexamphetamine
(dAMPH). Stimulants act upon the dopamine (DA) neuro-
transmitter system by increasing extracellular DA, and have
been shown to be very effective in reducing behavioral symp-
toms in ADHD (van de Loo-Neus et al. 2011). However, as
prescription rates of stimulants are rising (McCarthy et al.
2012), concern about potential long-term consequences of
stimulants on the developing DA system is increasingly
being voiced by a number of entities. These include
parents of patients, healthcare professionals, the Food
and Drug Administration (FDA) and National Institutes
of Health (NIH).
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Prospective studies are the ideal study design to investigate
the long-term effects of stimulants on the development of the
DA system. A prospective study in non-human primates
assessed the effects of 1-year treatment with MPH or placebo
during adolescence. This positron emission tomography
(PET) study found that the MPH group lacked the expected
age-related decline observed in the placebo group, suggestive
of increased D2/D3 receptors (Gill et al. 2012). In rats, juvenile
treatment with MPH reduced DA transporter (DAT) densities
immediately after treatment. When these rats were assessed in
adulthood, DAT densities were even further reduced. In adult-
treated rats, no such effect was observed (Moll et al. 2001).
Another prospective study in rats showed that early MPH
treatment persistently increased MPH-induced change in ce-
rebral blood volume (CBV) in the thalamus, cingulate and
medial prefrontal cortex (mPFC) later in life (Andersen et al.
2008). Behaviorally, juvenile MPH exposure reduced cocaine
self-administration (Andersen et al. 2002), but increased anx-
iety and depressive-like behaviors in rats (Bolaños et al. 2003;
Carlezon et al. 2003).
Human prospective studies are limited to short-term effects
(and treatment durations) for ethical reasons. Data from a re-
cent randomized controlled trial (RCT) from our group were
in line with the above mentioned preclinical work, showing
that four months of MPH treatment increased cerebral blood
flow (CBF) response to acute MPH, in children, but not in
adults with ADHD using phMRI (Schrantee et al. 2016).
However, to study the lasting effects of early stimulant treat-
ment, retrospective cohort studies can provide important in-
formation. For example, studies have shown both positive
(Biederman et al. 2009; Mannuzza et al. 2008; Wilens et al.
2003) and negative (Molina et al. 2009) associations between
stimulant treatment in adolescence and occurrence of
substance-use disorders (SUDs), as well as anxiety and de-
pressive disorders. However, the long-term effects of age-of-
first stimulant treatment on DA development have not yet
been studied in this context.
Taken together, the available evidence suggests that the
effects of stimulants on the DA system are dependent on
age-of-first-treatment, possibly reflecting ‘neurochemical im-
printing’ (Andersen and Navalta 2004). This theory also pre-
dicts that these effects are only fully expressed when the sys-
tem reaches maturation (e.g., typically during adulthood).
Using a cohort-study, we here studied the relation between
age-of-first-stimulant-exposure and the DA system using
pharmacological magnetic resonance imaging (phMRI).
phMRI is a non-invasive imaging technique to indirectly as-
sess DA function, which indirectly measures DA neurotrans-
mitter function by assessing hemodynamic changes induced
by a dopaminergic drug challenge. These phMRI signal
changes strongly correlate with DA release and DA transport-
er availability in preclinical and clinical studies (Chen et al.
1997; Schrantee et al. 2015).
We included three groups of adult ADHD patients: those
that had either been exposed to stimulants early in life (before
the age of 16), later in life (after the age of 23), or were naive
to stimulant treatment. Based on the literature, we hypothe-
sized a higher CBF response to an MPH challenge in early
exposed individuals compared to late exposed, or stimulant
treatment-naive individuals; higher anxiety and depression
scores in early but not late exposed, or stimulant treatment-
naive individuals; but less use of recreational drugs use in
early, but not late- or stimulant treatment-naive individuals.
Methods and materials
Participants
Eighty-one male ADHD patients (23–40 years) were recruited
via outpatient clinics, newspaper advertisements, databases
containing prescription data (Pharmo Institute Utrecht) and
the ePOD-MPH RCT (Schrantee et al. 2016). All subjects
had a clinical diagnosis of ADHD requiring pharmacological
treatment with a stimulant (diagnosed by psychiatrist, psy-
chologist or pediatrian (primarily) or GP according to DSM-
III or DSM-IV criteria according to Dutch treatment guide-
lines). Exclusion criteria were: IQ < 80, history of brain trau-
ma or neurological disease, MRI contra-indications and sub-
stance use (including cocaine, heroin, synthetic drugs, or al-
cohol) meeting diagnostic criteria for abuse/dependence.
Subjects were stratified into three exposure groups: 1) early
stimulant treatment (EST) group: subjects treated with stimu-
lants for at least four months before the age of 16 years 2) a
late stimulant treatment (LST) group: subjects treated with
stimulants for at least four months after the age of 23 years
and 3) a stimulant treatment-naive (STN) group: containing
subjects with no history of stimulant medication. Four months
of treatment was chosen in line with effects found on CBF in
MPH-treated children in a prospective study (Schrantee et al.
2016). The age limit of the EST group was chosen because
this coincides with the end of puberty in boys, and because
preclinical studies have reported effects of treatment in early
adolescence (Bottelier et al. 2014). Self-reported prescription
history were verified with available prescription data from
pharmacies and treating physicians. The study was carried
out in accordance with the Declaration of Helsinki (2012)
and was approved by the Medical Ethical Committee. All
subjects gave written informed consent.
Procedures
Subjects underwent two phMRI scan sessions, in which we
assessed the CBF response to an acute challenge toMPH, as a
proxy for DA functionality (Chen et al. 1997; Schrantee and
Reneman 2014). The first phMRI scan session was
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immediately followed by an oral challenge ofMPH of 0.5 mg/
kg MPH (with a maximum dose of 40 mg). The second scan
session was conducted after 90 min, which is the time after
which peak plasma levels of MPH are reached (Swanson and
Volkow 2003). In both sessions an arterial spin labeling (ASL)
scanwas obtained to assess CBF in the fronto-striatal circuitry.
All subjects were medication-free for at least a week before
the scan, to prevent acute effects of stimulant treatment on
CBF. In addition, subjects were instructed to abstain from
drugs of abuse at least one week before the study, alcohol at
least 24 h before the study and not to use caffeine or tobacco
on the study day.
MRI acquisition and image analysis
Data were acquired using a 3.0 T Philips MR Scanner (Philips
Medical Systems, Best, The Netherlands). First, an anatomical
3D–FFE T1-weighted scan was obtained with the following
scan parameters: TR/TE = 9.8/4.6; FOV = 256x256x120;
voxel size = 0.875 × 0.875 × 1.2 mm. CBF images were
acquired using a pseudo continuous arterial spin labeling
(pCASL) sequence with the following parameters: TR/
TE = 4000/14 ms; post-labeling delay = 1650 ms; label dura-
tion = 1525 ms; FOV = 240x240x119; 75 dynamics; voxel
size = 3x3x7mm, GE-EPI, SENSE = 2.5, no background sup-
pression, scan time = 10 min. Heart rate (HR) was monitored
using a peripheral pulse unit.
Data were processed using the Iris pipeline for CBF quan-
tification and multi-atlas region segmentation (Bron et al.
2014). All image registrations were performed using Elastix
registration software (Klein et al. 2010). For the ASL data,
motion estimation was performed using rigid registration with
a group-wise method that uses a similarity metric based on
principal component analysis. Then, outlier rejection was per-
formed to correct for sudden head movements. Outlier rejec-
tion was based on theMdiff images, the subtractions of all pairs
of control (Mc) and label images (Ml). For each pair of Mdiff
images, we computed the sum of squared differences (SSD)
which is the sum of all squared voxel-wise differences be-
tween the two images. As such, for each of the 75 time points,
we obtained 74 SSD values over which we computed the
median and SD. To obtain a more robust estimate of the SD,
we computed this based on only the SSD values that were
lower than the median. If more than 50% of the SSD values
were larger than the median + (3*SD) this timepoint was con-
sidered an outlier. Subsequently, motion correction was per-
formed on the remaining timepoints, and the resulting motion-
compensated Mdiff images were averaged to obtain a
perfusion-weighted image (ΔM). Motion was quantified as
the mean framewise displacement. Quantification of CBF
was performed using the single-compartment model (Buxton
et al. 1998), which is the recommended approach for pCASL
(Alsop et al. 2014). The following parameters were used: la-
beling efficiency αGM = 0.85, T1GM = 1.6 ms, blood-brain
partition coefficient λGM = 0.95 mL/g. The average of Mc
images was used as a proton-density normalization image
(M0) for the CBF quantification. Differences in post-labeling
delays between slices (due to the 2D read-out) were accounted
for. CBF was quantified in GM only, with a 3D method for
partial volume correction based on local linear regression
using the tissue probability maps (Asllani et al. 2008; Oliver
et al. 2012). For each subject, probabilistic GM segmentations
based on the T1-weighted scan (SPM8, Statistical Parametric
Mapping, UCL, London, UK) were rigidly registered to the
ΔM images by maximizing mutual information. For further
analysis, CBF maps were transformed to the space of the T1-
weighted scan. An example of a representative perfusion-
weighted image can be observed in Fig. 1.
For each participant, we defined three regions of interest
(ROIs) using a multi-atlas approach, registering 30 labeled
T1-weighted images (Gousias et al. 2008; Hammers et al.
2003) with the participants’ T1-weighted images. The labels
of the 30 atlas images were fused using a majority voting
algorithm to obtain a final ROI labeling (Heckemann et al.
2006). For three pre-defined ROIs, comprising the striatum,
thalamus and anterior cingulate cortex (ACC), CBF mean
values were extracted (Fig. 2). The striatum was selected be-
cause it is rich in DAT (the primary target of action of MPH)
and the thalamus and prefrontal cortex were chosen because
the animal literature demonstrated largest effects of early
MPH treatment using phMRI in these two important neuronal
projections from the striatum (Andersen et al. 2008).
Fig. 1 Axial view of a perfusion-weighted ASL scan from a representative subject
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Rating scales and questionnaires
Premorbid intellectual function was estimated using the
National Adult Reading test (Dutch version). Current
ADHD symptom severity was assessed using the ADHD-
Rating Scale (ADHD-RS) (Kooij et al. 2008). Current mood
and anxiety symptoms were evaluated using the Beck
Depression Inventory (BDI) and Beck Anxiety Inventory
(BAI), respectively. In addition, lifetime recreational drug
use was assessed using a drug history questionnaire.
Statistical analyses
SPSS version 22.0 (IBM, Armonk, NY, USA) was used for all
statistical testing. Data were assessed for normality. To assess
the effect of age-of-first-exposure on CBF response to MPH
we used a repeated-measures analysis of variance (ANOVA)
for each ROI separately with group (EST, LST or STN) as a
between-subjects factor and MPH-challenge (pre- or post-
MPH) as a within-subjects factor, with subsequent post-hoc
Sidak’s tests. Baseline differences in CBFwere assessed using
an univariate ANOVA. To further examine this age-dependen-
cy, we correlated age-of-first-exposure with CBF response
and mood symptoms in the LST and EST group. In additional
exploratory analyses, we assessed the effect of treatment du-
ration and time-since-last-use. Differences in recreational drug
use were assessed for cannabis, 3,4-methylenedioxy-metham-
phetamine (MDMA), cocaine and amphetamine using a χ2
test. To this end, subjects were divided in users (for cannabis
>1× per week, for other drugs >10× lifetime) and non-users.
Results
Patient characteristics
Age and estimated IQ differed statistically significantly be-
tween the three groups of ADHD subjects, with the EST group
being slightly younger and having a lower IQ than the STN
and LST group (Table 1). In addition, current symptom sever-
ity was significantly higher in the STN group compared to the
EST and LST group. Inherent to the design of the study, the
EST group started medication treatment at a younger age and
was treated for a much longer period of time (94.9 vs
11.8 months) than the LST group.
Fig. 2 a Regions of interest used
for analyses. Blue = striatum ;
green = anterior cingulate cortex;
yellow = thalamus. b change in
CBF (ml/100 g/min) following
acute MPH challenge (oral,
0.5 mg/kg) in the striatum,
thalamus and anterior cingulate
cortex (ACC). There was a main
effect of challenge in the striatum
and ACC, but not the thalamus.
We found no group*time
interaction in any of the ROIs.
Mean and standard error of the
mean are displayed. c scatter dot
plot of CBF baseline values (ml/
100 g/min) for all subjects. The
EST group demonstrated
significantly lower CBF than the
STN group in the ACC only
*p < 0.05. red = STN; green =
EST; blue = LST
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Baseline CBF and MPH-induced changes in CBF
One patient did not complete the second ASL scan and was
removed from the analysis. Motion during the MRI scan did
not differ between the three groups (baseline: F(2,78) = 1.13,
p = 0.33; change: F(2,78) = 0.75 p = 0.48). TheMPH challenge
increased HR (p < 0.01), but this effect did not differ between
the three groups (F(2,75) = 1.51 p = 0.23). ANOVA revealed a
significant effect of group on baseline CBF in the ACC
(F(2,78) = 3.62, p = 0.03), but not in the striatum
(F(2,78) = 2.07, p = 0.13) or thalamus (F(2,78) = 1.51,
p = 0.23). Post-hoc tests showed that the STN group had a
higher ACC CBF than the EST group (p = 0.03), but not com-
pared to the LST group (p = 0.36) (Fig. 2). The acute MPH
chal lenge reduced CBF (ΔCBF) in the str ia tum
(F(80,1) = 6.69, p = 0.01) and ACC (F(80,1) = 20.28,
p < 0.01), but not the thalamus (F(80,1) = 0.12, p = 0.73)
(Fig. 2). However, no significant interaction effects were
observed between group and ΔCBF in the ROIs studied, nor
did we find a significant correlation between ΔCBF and age-
of-first-exposure (r < 0.2 for all ROIs), treatment duration
(r < 0.1 for all ROIs) or time-since-last-treatment (r < 0.1 for
all ROIs). None of the results were affected by adding age,
ADHD symptom severity or baseline CBF values as covariates
to the model.
Depression, anxiety and recreational drug use
We found a significant overall effect of group on depressive
symptoms, (F(75,2) = 4.57, p = 0.01), but not on symptoms of
anxiety (F(76,2) = 1.38, p = 0.26). Post hoc analyses revealed
higher BDI scores in the EST than the LST group (p < 0.01).
The EST individuals indicated using less cannabis, MDMA,
cocaine as well as amphetamine than the LST and STN indi-
viduals, although this was only statistically significant for
cannabis and cocaine (Table 1).
Table 1 Participant
characteristics EST LST STN
N = 26 N = 29 N = 26
Mean SD Range Mean SD Range Mean SD Range
Age (years) 26.0 2.8 23–35 28.5 4.9 23–40 29.0 4.7 23–39*
Estimated IQ 100.3 8.0 82–113 108.0 8.6 92–124 107.7 6.4 95–118*
Median SD Range Median SD Range Median SD Range
Age first
stimulant
treatment
(years)
9.5 3.0 4–14 26 4.5 23–39 NA NA NA*
Treatment
duration
(months)
72 56.1 18–228 4 23.3 4–120 NA NA NA*
Time since last
treatment
(months)
84 57.2 0–168 0 1.3 0–6 NA NA NA*
ADHD-SR 23.2 10.0 1–45 21.8 7.6 10–39 30.4 10.3 8–50*
BDI 10.7 8.9 0–26 5.3 4.1 0–14 8.0 6.1 0–20*
BAI 8.5 8.7 0–35 6.3 4.9 0–18 9.4 7.7 0–25
Drug use
Cannabis (% of
subjects >
cutoff)a
25% 55% 60% *
MDMA (% of
subjects >
cutoff)b
13% 24% 31%
Cocaine (% of
subjects >
cutoff)b
0% 24% 19% *
Amphetamine
(% of subjects
> cutoff)b
0% 7% 8%
*p < 0.05
a more than once a week
b more than 10 x lifetime
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Discussion
Here we investigated if age of first stimulant exposure modu-
lates the effect CBF response to MPH, mood and anxiety
symptoms as well as recreational drug use. We did not find a
different CBF response to MPH between groups, but the EST
group showed lower baseline ACC CBF than the STN group,
which could be a result of early-induced changes by stimu-
lants to the developing DA system. In line with this, and as
hypothesized, the EST group showed higher depression- but
not anxiety-levels and reported less recreational drug use.
Long-term effects of stimulants on CBF
Modulation by age of stimulant exposure: baseline
To our knowledge, this is the first study investigating the long-
term effects of age-of-first-exposure on the DA system in
humans. The DA system is in development all throughout
childhood and adolescence. For example, cortical D2/D3 ex-
pression peaks in early childhood, followed by a sharp decline
during adolescence (Seeman et al. 1987), whereas dopamine
transporter (DAT) density peaks mid-adolescence while slow-
ly declining thereafter (Meng et al. 1999). In non-human pri-
mates MPH treatment during adolescence resulted in less de-
cline of striatal D2/D3 receptor binding following one year of
MPH treatment compared to the placebo group, suggesting
halted development of these receptors (Gill et al. 2012). In
line with that study, lower CBF in the ACC in the EST group
compared to the STN group, as we observed here, might re-
flect higher density of D2/D3 receptors induced by early treat-
ment, because experimental phMRI studies in rats have shown
that negative rCBV responses reflect agonism of D2/D3 recep-
tors, whereas positive rCBV changes are associated with
agonism of D1/D5 receptors (Chen et al. 2010). However, this
interpretation is speculative; Gill et al. (2012) found changes
in the striatum, whereas we reported changes in the ACC.
Future studies will need to study the changes in DA function
and connectivity within all areas of the fronto-thalamo-striatal
loops in more detail. Moreover, we did not find significant
differences in ACC CBF between the EST and LST group
and therefore caution is needed in interpreting the age-
dependency of this effect.
In accordance with predictions from the neuronal im-
printing theory, we did not find differences in baseline
CBF between the LST and STN group. This is in con-
trast with a study in adult ADHD patients, showing
increased DAT following one year of stimulant medica-
tion (Wang et al. 2013). Increased DAT availability
could result in lower CBF because of less availability
of extracellular DA, because less DA release results in
relatively more D2/D3 receptor stimulation. However,
they measured DAT 24 h after the last clinical dose of
MPH (Wang et al. 2013), whereas we conducted our
phMRI scans at least one week after treatment cessa-
tion. Although 24 h should ensure dissipation of acute
MPH effects, transient up-regulation of DAT cannot be
excluded in that study.
Modulation by age of stimulant exposure: MPH challenge
Our findings of reductions in CBF in the fronto-striatal circuit-
ry after an acute challenge with MPH are in agreement with
studies comparing on/off medication periods in adult ADHD
patients (O’Gorman et al. 2008; Schweitzer et al. 2003).
Studies in healthy volunteers report more mixed results. In
adult volunteers, MPH induced increased CBF in striatum
and thalamus in an ASL study (Marquand et al. 2012), but
increased CBF in the anterior cingulate, supplementary motor
areas and temporal poles in a H2[O
15] PET study (Udo de
Haes et al. 2007). Decreased CBF was reported in lateral fron-
tal, rostral cingulate and sensorimotor areas, amygdala,
parahippocampal gyrus and in multiple regions of the oc-
cipital and temporal cortices for the ASL study, but in
superior temporal gyri, right medial frontal gyrus, and
right inferior parietal cortex for the PET study. One reason
for the discrepancy between studies in volunteers and
ADHD patients might be altered DA release in ADHD
patients (Cherkasova et al. 2014; Volkow et al. 2007).
We found that in EST individuals with a mean treat-
ment duration of eight years, CBF response to MPH was
similar to that of LST and STN subjects. This finding was
in contrast to our hypothesis, as preclinical studies have
suggested that juvenile administration will result in DA
changes that will last and possibly even expand as the
brain matures (Moll et al. 2001). This hypothesis was
supported by our RCT showing that four months of
MPH treatment induced increased striatal and thalamic
CBF response to a MPH challenge in stimulant-
treatment naive children, but not adults with ADHD
(Schrantee et al. 2016). The current results suggest that
at least a part of this effect on the developing DA system
is transient or compensated. Interestingly, we did not find
a difference in CBF response to MPH between LST and
STN subjects, suggesting an absence of tolerance to
MPH following long-term treatment in adulthood.
Interestingly, Volkow et al. (2012), found reduced
striatal, but also no increased extrastriatal DA release to
a DA challenge after 12-month MPH treatment in adults
ADHD patients. Also in recreational dexamphetamine
(dAMPH) users we observed a blunted striatal CBF re-
sponse to dAMPH (Schrantee et al. 2015). However, rec-
reational use of stimulants is usually associated with high
dose binges, whereas much lower doses are used for
stimulant treatment of ADHD.
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Long-term modulating effect of age of stimulant exposure
on behavior
Although the short-term benefits of stimulants on ADHD
symptoms are well-established, studies on long-term efficacy
are inconclusive (van de Loo-Neus et al. 2011). Here, we
observed lower ADHD symptom severity in the EST and
LST group compared to the STN group, whereas the
stimulant-treated groups did not differ, despite the long time
since last exposure in the EST group. Our findings not only
suggest that MPH is useful in reducing symptoms in adult
ADHD (the LST group), but also suggests that the effects of
treatment in the EST group are long-lasting.
Animal studies have suggested an increased risk for de-
pressive symptoms following MPH exposure early in life
(Bolaños et al. 2008; Carlezon et al. 2003), but results from
human studies are equivocal (Biederman et al. 2009;
Mannuzza et al. 2008; Molina et al. 2009; Wilens et al.
2003). One limitation of our study is that, as a result of the
study design, children with both ADHD and depressive symp-
toms could have been more likely to receive treatment at
young age and thus end up in our EST group. In the current
study, we observed that EST subjects have more depressive
symptoms (~mild-moderate depression) than the other groups.
This is in line with a transient increased anxiety and depres-
sion in the MTA trial (Molina et al. 2009), but in contrast with
studies reporting protective effects of stimulant use on symp-
toms of anxiety and depression (Biederman et al. 2009; Daviss
et al. 2008; Lee et al. 2016).
In the current study we could not assess the effect of treat-
ment on SUDs, as this was an exclusion criterion; however a
large number of subjects in this sample were recreational drug
users. Interestingly, we found lower drug use in the EST group
compared to the STN and LST group, especially regarding
MDMA and cocaine use. This is line with literature showing
that whereas adult ADHD is associated with a high rate of
substance abuse (Dalsgaard et al. 2014), childhood treatment
does not increase (Humphreys et al. 2013; Molina et al. 2013),
and may even decrease this risk (Spencer et al. 2006). Our
findings are also consistent with the literature on self-
medication in ADHD (Wilens 2004), suggesting that ADHD
patients not taking stimulants are more likely to use drugs to
alleviate behavioral symptoms. An alternative explanation,
and not necessarily incompatible, is that lower vulnerability
for SUDs may be due to changes in the dopaminergic reward
system following early stimulant treatment.
Methodological considerations
The cohort we studied was heterogeneous in terms of
symptom onset, treatment duration, symptom severity
and probably also the course of the disorder.
Furthermore, the interaction between development, age-
of-first stimulant treatment, and duration of treatment is
likely not linear, which needs to be taken into account
for future studies. As a long-term RCT would not be
ethical, we have to rely on pre-clinical studies and ret-
rospective cross-sectional studies to inform us about
possible long-term effects of stimulants on the DA sys-
tem. Currently, many imaging initiatives are established
to share clinical and imaging data, which could facilitate
replication of small hypothesis-driven studies, such as
this one, in larger samples.
ASL-phMRI is an indirect method to measure neurotrans-
mitter function. Previous studies have shown that phMRI
closely parallels DA function (Chen et al. 1997).
Nevertheless, as we measure a vascular response to neuronal
function, it is possible that the CBF changes are caused by
alterations in other neurotransmitter systems, such as the nor-
adrenalin system, or mediated in part by cardiovascular ef-
fects. However, even though HR increased following MPH,
we did not find differences between the groups and therefore
cardiovascular effects are unlikely to explain our results. We
used a fixed-order, open-label design for two reasons; first,
CBF varies considerably across days and therefore a baseline
scan followed by an MPH scan was preferred. Second, partic-
ipants can easily discriminate between MPH and placebo and
therefore blinding was not possible in this study. Poly-drug
use is a limitation in this study and because of the high asso-
ciation between ADHD and drug (ab)use it is difficult to cor-
rect for or quantify the possible effect on our results. In addi-
tion, we cannot exclude that the increased depressive symp-
toms in the EST group are a pre-existing vulnerability, instead
of consequence of early stimulant treatment.
Conclusion
Our results suggest long-lasting effects of early stimu-
lant treatment on baseline CBF, ADHD symptoms,
mood as well as recreational drug use. Nevertheless,
we did not find lasting effects of stimulant exposure
on the phMRI response, suggesting that at least some
effects on the developing DA system are transient or
compensated for. It is likely that the neurochemical im-
printing effect of stimulant treatment on the DA system
is a dynamic process. Our data thus stress the need for
prospective follow-up studies including assessment at
multiple ages to completely characterize the long-term
effects of ADHD medication on the human brain.
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